gwi serum  (Sino Biological)


Bioz Verified Symbol Sino Biological is a verified supplier
Bioz Manufacturer Symbol Sino Biological manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
    Name:
    Influenza A H1N1 Hemagglutinin HA Antibody Rabbit PAb
    Description:
    Produced in rabbits immunized with purified recombinant Influenza A H1N1 A California 04 2009 Hemagglutinin HA Total IgG was purified by Protein A affinity chromatography
    Catalog Number:
    11055-rp01
    Price:
    None
    Applications:
    ELISA
    Host:
    Rabbit
    Immunogen:
    Influenza A H1N1 (A/California/04/2009) Hemagglutinin / HA Protein
    Category:
    Primary Antibody
    Antibody Type:
    PAb
    Isotype:
    Rabbit IgG
    Reactivity:
    H1N1
    		Buy from Supplier

    Structured Review

    Sino Biological gwi serum
    Ν2A cell apoptosis of cells in the presence of Gulf War illness <t>(GWI)</t> plus antibodies to cholera ( A ), influenza <t>A/H1N1</t> ( B ), influenza A/H3N2 ( C ) influenza B ( D ), hepatitis B ( E ), measles ( F ), S . Typhi ( G ), rabies ( H ), and mumps ( I ). The antibodies were added in the culture medium simultaneously with GWI serum for two days. Most nuclei appeared healthy and stained with DAPI (blue); few nuclei were stained with TUNEL in Figure 7 A–G (red). In Figure 7 H,I, antibodies against rabies and mumps are shown to have no effect, as most nuclei appear stained red with TUNEL.
    Produced in rabbits immunized with purified recombinant Influenza A H1N1 A California 04 2009 Hemagglutinin HA Total IgG was purified by Protein A affinity chromatography
    https://www.bioz.com/result/gwi serum/product/Sino Biological
    Average 93 stars, based on 5 article reviews
    Price from $9.99 to $1999.99
    gwi serum - by Bioz Stars, 2021-02
    93/100 stars

    Related Products / Commonly Used Together

    mouse antibodies
    β-actin
    gapdh
    pbs
    goat antibodies
    gfap
    gfp
    caspase-3
    mouse monoclonal antibodies
    ki67
    anti-mouse
    bax
    jagged1
    sox2
    bcl-xl

    Images

    1) Product Images from "Vaccine-Induced Adverse Effects in Cultured Neuroblastoma 2A (N2A) Cells Duplicate Toxicity of Serum from Patients with Gulf War Illness (GWI) and Are Prevented in the Presence of Specific Anti-Vaccine Antibodies"

    Article Title: Vaccine-Induced Adverse Effects in Cultured Neuroblastoma 2A (N2A) Cells Duplicate Toxicity of Serum from Patients with Gulf War Illness (GWI) and Are Prevented in the Presence of Specific Anti-Vaccine Antibodies

    Journal: Vaccines

    doi: 10.3390/vaccines8020232

    Ν2A cell apoptosis of cells in the presence of Gulf War illness (GWI) plus antibodies to cholera ( A ), influenza A/H1N1 ( B ), influenza A/H3N2 ( C ) influenza B ( D ), hepatitis B ( E ), measles ( F ), S . Typhi ( G ), rabies ( H ), and mumps ( I ). The antibodies were added in the culture medium simultaneously with GWI serum for two days. Most nuclei appeared healthy and stained with DAPI (blue); few nuclei were stained with TUNEL in Figure 7 A–G (red). In Figure 7 H,I, antibodies against rabies and mumps are shown to have no effect, as most nuclei appear stained red with TUNEL.
    Figure Legend Snippet: Ν2A cell apoptosis of cells in the presence of Gulf War illness (GWI) plus antibodies to cholera ( A ), influenza A/H1N1 ( B ), influenza A/H3N2 ( C ) influenza B ( D ), hepatitis B ( E ), measles ( F ), S . Typhi ( G ), rabies ( H ), and mumps ( I ). The antibodies were added in the culture medium simultaneously with GWI serum for two days. Most nuclei appeared healthy and stained with DAPI (blue); few nuclei were stained with TUNEL in Figure 7 A–G (red). In Figure 7 H,I, antibodies against rabies and mumps are shown to have no effect, as most nuclei appear stained red with TUNEL.

    Techniques Used: Staining, TUNEL Assay

    2) Product Images from "Antigenic Differences between AS03 Adjuvanted Influenza A (H1N1) Pandemic Vaccines: Implications for Pandemrix-Associated Narcolepsy Risk"

    Article Title: Antigenic Differences between AS03 Adjuvanted Influenza A (H1N1) Pandemic Vaccines: Implications for Pandemrix-Associated Narcolepsy Risk

    Journal: PLoS ONE

    doi: 10.1371/journal.pone.0114361

    Antibodies to untreated and detergent treated recombinant viral proteins studied by EIA. IgG-antibodies against untreated recombinant viral proteins, rHA (A) and rNP (B), and against rHA and rNP exposed to non-ionic detergents, Triton X and polysorbate 80 (PS80), used in the manufacturing process of Pandemrix H1N1 antigen, but not Arepanrix, in six plasma samples from vaccinated children with narcolepsy C. Children with narcolepsy (N; n = 47) had higher levels of IgG-antibodies to polysorbate 80 treated recombinant NP (PS80) but not to untreated NP (PBS) than healthy vaccinated children (C; n = 57). Children with narcolepsy who all carry HLA DQB1*06∶02 allele (N; n = 47) and healthy vaccinated children with HLA DQB1*06∶02 allele (C/DQ6+; n = 20)) had higher levels of antibodies to untreated NP in comparison to the children without HLA DQB1*06∶02 allele (C/DQ6−; n = 37). D. Children with narcolepsy (N; n = 47) showed higher levels of IgG-antibodies to untreated recombinant HA (PBS) and polysorbate 80 treated HA (PS80) than healthy vaccinated children (C; n = 57). No difference was found in the antibody levels to treated or untreated HA between healthy children with or without HLA DQB1*06∶02 allele (C/DQ6+; n = 20 and C/DQ6−; n = 37).
    Figure Legend Snippet: Antibodies to untreated and detergent treated recombinant viral proteins studied by EIA. IgG-antibodies against untreated recombinant viral proteins, rHA (A) and rNP (B), and against rHA and rNP exposed to non-ionic detergents, Triton X and polysorbate 80 (PS80), used in the manufacturing process of Pandemrix H1N1 antigen, but not Arepanrix, in six plasma samples from vaccinated children with narcolepsy C. Children with narcolepsy (N; n = 47) had higher levels of IgG-antibodies to polysorbate 80 treated recombinant NP (PS80) but not to untreated NP (PBS) than healthy vaccinated children (C; n = 57). Children with narcolepsy who all carry HLA DQB1*06∶02 allele (N; n = 47) and healthy vaccinated children with HLA DQB1*06∶02 allele (C/DQ6+; n = 20)) had higher levels of antibodies to untreated NP in comparison to the children without HLA DQB1*06∶02 allele (C/DQ6−; n = 37). D. Children with narcolepsy (N; n = 47) showed higher levels of IgG-antibodies to untreated recombinant HA (PBS) and polysorbate 80 treated HA (PS80) than healthy vaccinated children (C; n = 57). No difference was found in the antibody levels to treated or untreated HA between healthy children with or without HLA DQB1*06∶02 allele (C/DQ6+; n = 20 and C/DQ6−; n = 37).

    Techniques Used: Recombinant, Enzyme-linked Immunosorbent Assay

    IgG-antibody levels to detergent treated recombinant HA (A) and NP (B) in the Pandemrix immunized mice transgenic for HLA DQB1*06∶02 (DQ6 Pand) or HLA DQB1*03∶02 (DQ8 Pand) and in the HLA DQB1*06∶02 transgenic mice immunized with PBS (DQ6 ctrl). IgG-antibodies to rNP are higher in the immunized HLA DQB1*06∶02 (DQ6 Pand) than in the immunized HLA DQB1*03∶02 transgenic mice (DQ8 Pand), whereas no difference is seen in the antibody levels to rHA in the EIA.
    Figure Legend Snippet: IgG-antibody levels to detergent treated recombinant HA (A) and NP (B) in the Pandemrix immunized mice transgenic for HLA DQB1*06∶02 (DQ6 Pand) or HLA DQB1*03∶02 (DQ8 Pand) and in the HLA DQB1*06∶02 transgenic mice immunized with PBS (DQ6 ctrl). IgG-antibodies to rNP are higher in the immunized HLA DQB1*06∶02 (DQ6 Pand) than in the immunized HLA DQB1*03∶02 transgenic mice (DQ8 Pand), whereas no difference is seen in the antibody levels to rHA in the EIA.

    Techniques Used: Recombinant, Mouse Assay, Transgenic Assay, Enzyme-linked Immunosorbent Assay

    The IgG-antibody levels to H1N1 antigen suspension of Pandemrix (A), tetanus toxoid (B) and neutralizing antibody levels to Polio Sabin vaccine virus (C) in 47 children with narcolepsy (N) and 57 healthy vaccinated children with and without HLA DQB1*06∶02 risk allele of narcolepsy (C/DQ6+ and C/DQ6−). Antibodies to Pandemrix H1N1 antigen and tetanus toxoid were determined by EIA and the results expressed as optical density units (y-axis).
    Figure Legend Snippet: The IgG-antibody levels to H1N1 antigen suspension of Pandemrix (A), tetanus toxoid (B) and neutralizing antibody levels to Polio Sabin vaccine virus (C) in 47 children with narcolepsy (N) and 57 healthy vaccinated children with and without HLA DQB1*06∶02 risk allele of narcolepsy (C/DQ6+ and C/DQ6−). Antibodies to Pandemrix H1N1 antigen and tetanus toxoid were determined by EIA and the results expressed as optical density units (y-axis).

    Techniques Used: Enzyme-linked Immunosorbent Assay

    A sandwich EIA for the detection of IgG-antibodies to H1N1 proteins captured from H1N1 antigen of Pandemrix with solid-phase bound antibodies to HA, NA and NP. A. Capture of H1N1 viral proteins from Pandemrix antigen in a sandwich EIA revealed that HA and NA are found in a complex in the Pandemrix H1N1 antigen, whereas NP does not complex with HA or NA. H1N1 viral proteins from Pandemrix vaccine were captured with rabbit monoclonal anti-HA, anti-NA and anti-NP antibodies bound to EIA plate and mouse monoclonal anti-HA, anti-NA and anti-NP antibodies were used as the detection antibodies. B. IgG-antibodies binding to Pandemrix derived NP were higher in children with narcolepsy (N; n = 47) than in vaccinated healthy children(C; n = 57) when studied with sandwich EIA using anti-NP antibody to capture NP from Pandemrix H1N1 antigen suspension. The children with narcolepsy (N) had higher levels of IgG-antibodies to Pandemrix derived NP than the healthy, vaccinated children without HLA DQB1*06∶02 risk allele (C/DQ6−; n = 37), whereas no difference was seen in comparison with the healthy, vaccinated children with HLA DQB1*06∶02 risk allele (C/DQ6+; n = 20).
    Figure Legend Snippet: A sandwich EIA for the detection of IgG-antibodies to H1N1 proteins captured from H1N1 antigen of Pandemrix with solid-phase bound antibodies to HA, NA and NP. A. Capture of H1N1 viral proteins from Pandemrix antigen in a sandwich EIA revealed that HA and NA are found in a complex in the Pandemrix H1N1 antigen, whereas NP does not complex with HA or NA. H1N1 viral proteins from Pandemrix vaccine were captured with rabbit monoclonal anti-HA, anti-NA and anti-NP antibodies bound to EIA plate and mouse monoclonal anti-HA, anti-NA and anti-NP antibodies were used as the detection antibodies. B. IgG-antibodies binding to Pandemrix derived NP were higher in children with narcolepsy (N; n = 47) than in vaccinated healthy children(C; n = 57) when studied with sandwich EIA using anti-NP antibody to capture NP from Pandemrix H1N1 antigen suspension. The children with narcolepsy (N) had higher levels of IgG-antibodies to Pandemrix derived NP than the healthy, vaccinated children without HLA DQB1*06∶02 risk allele (C/DQ6−; n = 37), whereas no difference was seen in comparison with the healthy, vaccinated children with HLA DQB1*06∶02 risk allele (C/DQ6+; n = 20).

    Techniques Used: Enzyme-linked Immunosorbent Assay, Binding Assay, Derivative Assay

    3) Product Images from "Vaccine-Induced Adverse Effects in Cultured Neuroblastoma 2A (N2A) Cells Duplicate Toxicity of Serum from Patients with Gulf War Illness (GWI) and Are Prevented in the Presence of Specific Anti-Vaccine Antibodies"

    Article Title: Vaccine-Induced Adverse Effects in Cultured Neuroblastoma 2A (N2A) Cells Duplicate Toxicity of Serum from Patients with Gulf War Illness (GWI) and Are Prevented in the Presence of Specific Anti-Vaccine Antibodies

    Journal: Vaccines

    doi: 10.3390/vaccines8020232

    Ν2A cell apoptosis of cells in the presence of Gulf War illness (GWI) plus antibodies to cholera ( A ), influenza A/H1N1 ( B ), influenza A/H3N2 ( C ) influenza B ( D ), hepatitis B ( E ), measles ( F ), S . Typhi ( G ), rabies ( H ), and mumps ( I ). The antibodies were added in the culture medium simultaneously with GWI serum for two days. Most nuclei appeared healthy and stained with DAPI (blue); few nuclei were stained with TUNEL in Figure 7 A–G (red). In Figure 7 H,I, antibodies against rabies and mumps are shown to have no effect, as most nuclei appear stained red with TUNEL.
    Figure Legend Snippet: Ν2A cell apoptosis of cells in the presence of Gulf War illness (GWI) plus antibodies to cholera ( A ), influenza A/H1N1 ( B ), influenza A/H3N2 ( C ) influenza B ( D ), hepatitis B ( E ), measles ( F ), S . Typhi ( G ), rabies ( H ), and mumps ( I ). The antibodies were added in the culture medium simultaneously with GWI serum for two days. Most nuclei appeared healthy and stained with DAPI (blue); few nuclei were stained with TUNEL in Figure 7 A–G (red). In Figure 7 H,I, antibodies against rabies and mumps are shown to have no effect, as most nuclei appear stained red with TUNEL.

    Techniques Used: Staining, TUNEL Assay

    4) Product Images from "Antigenic Differences between AS03 Adjuvanted Influenza A (H1N1) Pandemic Vaccines: Implications for Pandemrix-Associated Narcolepsy Risk"

    Article Title: Antigenic Differences between AS03 Adjuvanted Influenza A (H1N1) Pandemic Vaccines: Implications for Pandemrix-Associated Narcolepsy Risk

    Journal: PLoS ONE

    doi: 10.1371/journal.pone.0114361

    Antibodies to untreated and detergent treated recombinant viral proteins studied by EIA. IgG-antibodies against untreated recombinant viral proteins, rHA (A) and rNP (B), and against rHA and rNP exposed to non-ionic detergents, Triton X and polysorbate 80 (PS80), used in the manufacturing process of Pandemrix H1N1 antigen, but not Arepanrix, in six plasma samples from vaccinated children with narcolepsy C. Children with narcolepsy (N; n = 47) had higher levels of IgG-antibodies to polysorbate 80 treated recombinant NP (PS80) but not to untreated NP (PBS) than healthy vaccinated children (C; n = 57). Children with narcolepsy who all carry HLA DQB1*06∶02 allele (N; n = 47) and healthy vaccinated children with HLA DQB1*06∶02 allele (C/DQ6+; n = 20)) had higher levels of antibodies to untreated NP in comparison to the children without HLA DQB1*06∶02 allele (C/DQ6−; n = 37). D. Children with narcolepsy (N; n = 47) showed higher levels of IgG-antibodies to untreated recombinant HA (PBS) and polysorbate 80 treated HA (PS80) than healthy vaccinated children (C; n = 57). No difference was found in the antibody levels to treated or untreated HA between healthy children with or without HLA DQB1*06∶02 allele (C/DQ6+; n = 20 and C/DQ6−; n = 37).
    Figure Legend Snippet: Antibodies to untreated and detergent treated recombinant viral proteins studied by EIA. IgG-antibodies against untreated recombinant viral proteins, rHA (A) and rNP (B), and against rHA and rNP exposed to non-ionic detergents, Triton X and polysorbate 80 (PS80), used in the manufacturing process of Pandemrix H1N1 antigen, but not Arepanrix, in six plasma samples from vaccinated children with narcolepsy C. Children with narcolepsy (N; n = 47) had higher levels of IgG-antibodies to polysorbate 80 treated recombinant NP (PS80) but not to untreated NP (PBS) than healthy vaccinated children (C; n = 57). Children with narcolepsy who all carry HLA DQB1*06∶02 allele (N; n = 47) and healthy vaccinated children with HLA DQB1*06∶02 allele (C/DQ6+; n = 20)) had higher levels of antibodies to untreated NP in comparison to the children without HLA DQB1*06∶02 allele (C/DQ6−; n = 37). D. Children with narcolepsy (N; n = 47) showed higher levels of IgG-antibodies to untreated recombinant HA (PBS) and polysorbate 80 treated HA (PS80) than healthy vaccinated children (C; n = 57). No difference was found in the antibody levels to treated or untreated HA between healthy children with or without HLA DQB1*06∶02 allele (C/DQ6+; n = 20 and C/DQ6−; n = 37).

    Techniques Used: Recombinant, Enzyme-linked Immunosorbent Assay

    High-resolution MES-PAGE analysis of Pandemrix and Arepandrix vaccines under reducing and non-reducing conditions. Pandemrix H1N1 antigen suspension run under reducing conditions (A) with a major band including a mixture of HA and NP, and under non-reducing conditions (B) with HA shown in the upper area and NP at its original place identical to RF position of the reducing gel (A). Recombinant NP from H1N1/A/Puerto Rico 1934 (Sino Biologicals Inc., China) alone run under reducing conditions (C). HA stained with monoclonal mouse anti-HA antibody (Sino Biologicals Inc., China) using western blotting of the separated proteins of Pandemrix H1N1 antigen suspension under non-reducing conditions (D) and under reducing conditions (E). Arepanrix H1N1 antigen suspension run under reducing conditions (F) with a major band including a mixture of HA and NP (F), and run under non-reducing conditions (G) with HA shown in the upper area and NP at its original place identical to RF position of the reducing gel (F).
    Figure Legend Snippet: High-resolution MES-PAGE analysis of Pandemrix and Arepandrix vaccines under reducing and non-reducing conditions. Pandemrix H1N1 antigen suspension run under reducing conditions (A) with a major band including a mixture of HA and NP, and under non-reducing conditions (B) with HA shown in the upper area and NP at its original place identical to RF position of the reducing gel (A). Recombinant NP from H1N1/A/Puerto Rico 1934 (Sino Biologicals Inc., China) alone run under reducing conditions (C). HA stained with monoclonal mouse anti-HA antibody (Sino Biologicals Inc., China) using western blotting of the separated proteins of Pandemrix H1N1 antigen suspension under non-reducing conditions (D) and under reducing conditions (E). Arepanrix H1N1 antigen suspension run under reducing conditions (F) with a major band including a mixture of HA and NP (F), and run under non-reducing conditions (G) with HA shown in the upper area and NP at its original place identical to RF position of the reducing gel (F).

    Techniques Used: Polyacrylamide Gel Electrophoresis, Recombinant, Staining, Western Blot

    Western-blot analysis of the presence of NP in Pandemrix and Arepanrix H1N1 antigen suspension. Pandemrix and Arepanrix H1N1 antigen suspensions were run under reducing conditions and NP stained with monoclonal mouse NP-antibody (Sino Biologicals Inc., China).
    Figure Legend Snippet: Western-blot analysis of the presence of NP in Pandemrix and Arepanrix H1N1 antigen suspension. Pandemrix and Arepanrix H1N1 antigen suspensions were run under reducing conditions and NP stained with monoclonal mouse NP-antibody (Sino Biologicals Inc., China).

    Techniques Used: Western Blot, Staining

    Dot blot detection of viral proteins with mouse monoclonal anti-HA, anti-NA and anti-NP antibodies (Sino Biologicals Inc., China) in the density fractions isolated with gradient ultracentrifugation from Pandemrix H1N1 antigen suspension. HA and NA was detected as lipid-protein micelles in the density fraction corresponding density between 1.063–1.21 g/mL, and soluble HA, NA and NP were detected in the density fraction above 1.21 g/mL.
    Figure Legend Snippet: Dot blot detection of viral proteins with mouse monoclonal anti-HA, anti-NA and anti-NP antibodies (Sino Biologicals Inc., China) in the density fractions isolated with gradient ultracentrifugation from Pandemrix H1N1 antigen suspension. HA and NA was detected as lipid-protein micelles in the density fraction corresponding density between 1.063–1.21 g/mL, and soluble HA, NA and NP were detected in the density fraction above 1.21 g/mL.

    Techniques Used: Dot Blot, Isolation

    High-resolution MES-PAGE analysis of Arepanrix (lane A) and Pandemrix (lane B) H1N1 antigen suspensions under reducing conditions, and immunostaining of the separated proteins in Pandemrix by western blotting using anti-NP antibody (C). A set of sharp bands at approximately 120 kDa molecular weight could be seen in Pandemrix (B) but not in Arepanrix sample (A). These bands in Pandemrix were identified by mass spectrometry to be polymeric forms of the influenza virus nucleoprotein (NP) and by western blotting with anti-NP antibody (C).
    Figure Legend Snippet: High-resolution MES-PAGE analysis of Arepanrix (lane A) and Pandemrix (lane B) H1N1 antigen suspensions under reducing conditions, and immunostaining of the separated proteins in Pandemrix by western blotting using anti-NP antibody (C). A set of sharp bands at approximately 120 kDa molecular weight could be seen in Pandemrix (B) but not in Arepanrix sample (A). These bands in Pandemrix were identified by mass spectrometry to be polymeric forms of the influenza virus nucleoprotein (NP) and by western blotting with anti-NP antibody (C).

    Techniques Used: Polyacrylamide Gel Electrophoresis, Immunostaining, Western Blot, Molecular Weight, Mass Spectrometry

    The IgG-antibody levels to H1N1 antigen suspension of Pandemrix (A), tetanus toxoid (B) and neutralizing antibody levels to Polio Sabin vaccine virus (C) in 47 children with narcolepsy (N) and 57 healthy vaccinated children with and without HLA DQB1*06∶02 risk allele of narcolepsy (C/DQ6+ and C/DQ6−). Antibodies to Pandemrix H1N1 antigen and tetanus toxoid were determined by EIA and the results expressed as optical density units (y-axis).
    Figure Legend Snippet: The IgG-antibody levels to H1N1 antigen suspension of Pandemrix (A), tetanus toxoid (B) and neutralizing antibody levels to Polio Sabin vaccine virus (C) in 47 children with narcolepsy (N) and 57 healthy vaccinated children with and without HLA DQB1*06∶02 risk allele of narcolepsy (C/DQ6+ and C/DQ6−). Antibodies to Pandemrix H1N1 antigen and tetanus toxoid were determined by EIA and the results expressed as optical density units (y-axis).

    Techniques Used: Enzyme-linked Immunosorbent Assay

    A sandwich EIA for the detection of IgG-antibodies to H1N1 proteins captured from H1N1 antigen of Pandemrix with solid-phase bound antibodies to HA, NA and NP. A. Capture of H1N1 viral proteins from Pandemrix antigen in a sandwich EIA revealed that HA and NA are found in a complex in the Pandemrix H1N1 antigen, whereas NP does not complex with HA or NA. H1N1 viral proteins from Pandemrix vaccine were captured with rabbit monoclonal anti-HA, anti-NA and anti-NP antibodies bound to EIA plate and mouse monoclonal anti-HA, anti-NA and anti-NP antibodies were used as the detection antibodies. B. IgG-antibodies binding to Pandemrix derived NP were higher in children with narcolepsy (N; n = 47) than in vaccinated healthy children(C; n = 57) when studied with sandwich EIA using anti-NP antibody to capture NP from Pandemrix H1N1 antigen suspension. The children with narcolepsy (N) had higher levels of IgG-antibodies to Pandemrix derived NP than the healthy, vaccinated children without HLA DQB1*06∶02 risk allele (C/DQ6−; n = 37), whereas no difference was seen in comparison with the healthy, vaccinated children with HLA DQB1*06∶02 risk allele (C/DQ6+; n = 20).
    Figure Legend Snippet: A sandwich EIA for the detection of IgG-antibodies to H1N1 proteins captured from H1N1 antigen of Pandemrix with solid-phase bound antibodies to HA, NA and NP. A. Capture of H1N1 viral proteins from Pandemrix antigen in a sandwich EIA revealed that HA and NA are found in a complex in the Pandemrix H1N1 antigen, whereas NP does not complex with HA or NA. H1N1 viral proteins from Pandemrix vaccine were captured with rabbit monoclonal anti-HA, anti-NA and anti-NP antibodies bound to EIA plate and mouse monoclonal anti-HA, anti-NA and anti-NP antibodies were used as the detection antibodies. B. IgG-antibodies binding to Pandemrix derived NP were higher in children with narcolepsy (N; n = 47) than in vaccinated healthy children(C; n = 57) when studied with sandwich EIA using anti-NP antibody to capture NP from Pandemrix H1N1 antigen suspension. The children with narcolepsy (N) had higher levels of IgG-antibodies to Pandemrix derived NP than the healthy, vaccinated children without HLA DQB1*06∶02 risk allele (C/DQ6−; n = 37), whereas no difference was seen in comparison with the healthy, vaccinated children with HLA DQB1*06∶02 risk allele (C/DQ6+; n = 20).

    Techniques Used: Enzyme-linked Immunosorbent Assay, Binding Assay, Derivative Assay

    The in vitro inhibition of IgG-antibodies binding to H1N1 antigen of Pandemrix is evaluated using H1N1 antigen suspension of Pandemrix, Arepanrix or detergents present in Pandemrix as liquid-phase inhibitors pre-incubated with plasma samples from study subjects. A. The inhibition of IgG-antibodies binding to solid-phase bound H1N1 antigen of Pandemrix (% of inhibition in y-axis) is lower when Arepanrix antigen (1/10) is used as inhibitor compared to Pandemrix (1/10) as an inhibitor both in children with narcolepsy (N; n = 47) and in healthy vaccinated children (C; n = 57). B. The inhibition of IgG-antibodies binding to solid-phase bound H1N1 antigen of Pandemrix (% of inhibition in y-axis) with Arepanrix antigen(1/10) is weaker in the children with narcolepsy who are homozygotic for HLA DQB1*06∶02 risk allele than in the children with narcolepsy or healthy children who are heterozygotic for HLA DQB1*06∶02 risk allele of narcolepsy. C. Dose-dependent inhibition of IgG-antibodies binding to solid-phase bound H1N1 antigen of Pandemrix (% of inhibition in y-axis) using as a liquid phase inhibitor H1N1 antigen suspension of Arepanrix or Pandemrix at the final dilutions of 1/250, 1/50 and 1/10 (0.4, 2, 10 on x-axis) or the detergents present in the H1N1 antigen suspension of Pandemrix, Triton X and polysorbate 80, at the final concentrations 0.8, 4, and 20 µg/mL (0.4, 2, 10 on axis). The inhibition curves represent mean value of the % of inhibition in plasma samples from 3 children with narcolepsy.
    Figure Legend Snippet: The in vitro inhibition of IgG-antibodies binding to H1N1 antigen of Pandemrix is evaluated using H1N1 antigen suspension of Pandemrix, Arepanrix or detergents present in Pandemrix as liquid-phase inhibitors pre-incubated with plasma samples from study subjects. A. The inhibition of IgG-antibodies binding to solid-phase bound H1N1 antigen of Pandemrix (% of inhibition in y-axis) is lower when Arepanrix antigen (1/10) is used as inhibitor compared to Pandemrix (1/10) as an inhibitor both in children with narcolepsy (N; n = 47) and in healthy vaccinated children (C; n = 57). B. The inhibition of IgG-antibodies binding to solid-phase bound H1N1 antigen of Pandemrix (% of inhibition in y-axis) with Arepanrix antigen(1/10) is weaker in the children with narcolepsy who are homozygotic for HLA DQB1*06∶02 risk allele than in the children with narcolepsy or healthy children who are heterozygotic for HLA DQB1*06∶02 risk allele of narcolepsy. C. Dose-dependent inhibition of IgG-antibodies binding to solid-phase bound H1N1 antigen of Pandemrix (% of inhibition in y-axis) using as a liquid phase inhibitor H1N1 antigen suspension of Arepanrix or Pandemrix at the final dilutions of 1/250, 1/50 and 1/10 (0.4, 2, 10 on x-axis) or the detergents present in the H1N1 antigen suspension of Pandemrix, Triton X and polysorbate 80, at the final concentrations 0.8, 4, and 20 µg/mL (0.4, 2, 10 on axis). The inhibition curves represent mean value of the % of inhibition in plasma samples from 3 children with narcolepsy.

    Techniques Used: In Vitro, Inhibition, Binding Assay, Incubation

    Related Articles

    Incubation:

    Article Title: Vaccine-Induced Adverse Effects in Cultured Neuroblastoma 2A (N2A) Cells Duplicate Toxicity of Serum from Patients with Gulf War Illness (GWI) and Are Prevented in the Presence of Specific Anti-Vaccine Antibodies
    Article Snippet: .. For this assay, the following antibodies were each incubated with GWI serum: anti-hemagglutinin (HA)–H1N1 (Cat. No. 11055-RP01), anti-HA–H3N2 (Cat. No. 11715-RP01), anti-HA–B (Cat. No.11053-RP01), strains of influenza (polyclonal, Sino Biological, Wayne, PA, USA); anti-Salmonella (Cat. No. PA1-20811, polyclonal, ThermoFisher Scientific, Rockford, IL, USA); anti-Japanese encephalitis virus (Cat. No. PA5-32237, polyclonal, ThermoFisher Scientific, Rockford, IL, USA); anti-Yersinia pestis (Cat. No. MA1-23074, monoclonal, ThermoFisher Scientific, Rockford, IL, USA); anti-hepatitis virus B (Cat. No. ab9193, polyclonal, Abcam, Cambridge, UK); anti-cholera toxin (monoclonal, Cat. No. LS-C142039, LS Bio, Seattle, WA, USA); anti-Yellow fever (Cat. No.3576, ThermoFisher Scientific, Rockford, IL, USA); anti-varicella zoster (Cat. No.LS-132860/58089, LS Bio, Seattle, WA, USA); anti-anthrax protective antigen (Cat. No. CPBT-66806RA, polyclonal, Creative Diagnostics, Shirley, NJ, USA); anti-mumps virus (Cat. No. MBS320375, monoclonal, MyBioSource, San Diego, CA, USA); anti-adenovirus (Cat. No. LS-C63691/120157, Seattle, WA, USA); anti-polio virus (Cat. No. ab22450, monoclonal, abcam, Cambridge, UK); anti-clostridium botulinum B toxoid activity (polyclonal, Cat. No. ab83064, abcam, Cambridge, UK); anti-measles (monoclonal, Cat. No. DMABT-H21849 Creative Diagnosticss, Shirley, NJ, USA). .. Antibodies were titrated for effects at a series of concentrations following pre-incubation with GWI serum and used at the lowest active concentration of 5–10 μg/mL each.

    Activity Assay:

    Article Title: Vaccine-Induced Adverse Effects in Cultured Neuroblastoma 2A (N2A) Cells Duplicate Toxicity of Serum from Patients with Gulf War Illness (GWI) and Are Prevented in the Presence of Specific Anti-Vaccine Antibodies
    Article Snippet: .. For this assay, the following antibodies were each incubated with GWI serum: anti-hemagglutinin (HA)–H1N1 (Cat. No. 11055-RP01), anti-HA–H3N2 (Cat. No. 11715-RP01), anti-HA–B (Cat. No.11053-RP01), strains of influenza (polyclonal, Sino Biological, Wayne, PA, USA); anti-Salmonella (Cat. No. PA1-20811, polyclonal, ThermoFisher Scientific, Rockford, IL, USA); anti-Japanese encephalitis virus (Cat. No. PA5-32237, polyclonal, ThermoFisher Scientific, Rockford, IL, USA); anti-Yersinia pestis (Cat. No. MA1-23074, monoclonal, ThermoFisher Scientific, Rockford, IL, USA); anti-hepatitis virus B (Cat. No. ab9193, polyclonal, Abcam, Cambridge, UK); anti-cholera toxin (monoclonal, Cat. No. LS-C142039, LS Bio, Seattle, WA, USA); anti-Yellow fever (Cat. No.3576, ThermoFisher Scientific, Rockford, IL, USA); anti-varicella zoster (Cat. No.LS-132860/58089, LS Bio, Seattle, WA, USA); anti-anthrax protective antigen (Cat. No. CPBT-66806RA, polyclonal, Creative Diagnostics, Shirley, NJ, USA); anti-mumps virus (Cat. No. MBS320375, monoclonal, MyBioSource, San Diego, CA, USA); anti-adenovirus (Cat. No. LS-C63691/120157, Seattle, WA, USA); anti-polio virus (Cat. No. ab22450, monoclonal, abcam, Cambridge, UK); anti-clostridium botulinum B toxoid activity (polyclonal, Cat. No. ab83064, abcam, Cambridge, UK); anti-measles (monoclonal, Cat. No. DMABT-H21849 Creative Diagnosticss, Shirley, NJ, USA). .. Antibodies were titrated for effects at a series of concentrations following pre-incubation with GWI serum and used at the lowest active concentration of 5–10 μg/mL each.

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • recombinant influenza ha  (Sino Biological)
    90
    Sino Biological recombinant influenza ha
    Recombinant Influenza Ha, supplied by Sino Biological, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant influenza ha/product/Sino Biological
    Average 90 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    recombinant influenza ha - by Bioz Stars, 2021-02
    90/100 stars
    		  Buy from Supplier
    gwi serum  (Sino Biological)
    93
    Sino Biological gwi serum
    Ν2A cell apoptosis of cells in the presence of Gulf War illness <t>(GWI)</t> plus antibodies to cholera ( A ), influenza <t>A/H1N1</t> ( B ), influenza A/H3N2 ( C ) influenza B ( D ), hepatitis B ( E ), measles ( F ), S . Typhi ( G ), rabies ( H ), and mumps ( I ). The antibodies were added in the culture medium simultaneously with GWI serum for two days. Most nuclei appeared healthy and stained with DAPI (blue); few nuclei were stained with TUNEL in Figure 7 A–G (red). In Figure 7 H,I, antibodies against rabies and mumps are shown to have no effect, as most nuclei appear stained red with TUNEL.
    Gwi Serum, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gwi serum/product/Sino Biological
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    gwi serum - by Bioz Stars, 2021-02
    93/100 stars
    		  Buy from Supplier
    influenza a h1n1 hemagglutinin ha antibody rabbit pab  (Sino Biological)
    93
    Sino Biological influenza a h1n1 hemagglutinin ha antibody rabbit pab
    Ν2A cell apoptosis of cells in the presence of Gulf War illness <t>(GWI)</t> plus antibodies to cholera ( A ), influenza <t>A/H1N1</t> ( B ), influenza A/H3N2 ( C ) influenza B ( D ), hepatitis B ( E ), measles ( F ), S . Typhi ( G ), rabies ( H ), and mumps ( I ). The antibodies were added in the culture medium simultaneously with GWI serum for two days. Most nuclei appeared healthy and stained with DAPI (blue); few nuclei were stained with TUNEL in Figure 7 A–G (red). In Figure 7 H,I, antibodies against rabies and mumps are shown to have no effect, as most nuclei appear stained red with TUNEL.
    Influenza A H1n1 Hemagglutinin Ha Antibody Rabbit Pab, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/influenza a h1n1 hemagglutinin ha antibody rabbit pab/product/Sino Biological
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    influenza a h1n1 hemagglutinin ha antibody rabbit pab - by Bioz Stars, 2021-02
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Ν2A cell apoptosis of cells in the presence of Gulf War illness (GWI) plus antibodies to cholera ( A ), influenza A/H1N1 ( B ), influenza A/H3N2 ( C ) influenza B ( D ), hepatitis B ( E ), measles ( F ), S . Typhi ( G ), rabies ( H ), and mumps ( I ). The antibodies were added in the culture medium simultaneously with GWI serum for two days. Most nuclei appeared healthy and stained with DAPI (blue); few nuclei were stained with TUNEL in Figure 7 A–G (red). In Figure 7 H,I, antibodies against rabies and mumps are shown to have no effect, as most nuclei appear stained red with TUNEL.

    Journal: Vaccines

    Article Title: Vaccine-Induced Adverse Effects in Cultured Neuroblastoma 2A (N2A) Cells Duplicate Toxicity of Serum from Patients with Gulf War Illness (GWI) and Are Prevented in the Presence of Specific Anti-Vaccine Antibodies

    doi: 10.3390/vaccines8020232

    Figure Lengend Snippet: Ν2A cell apoptosis of cells in the presence of Gulf War illness (GWI) plus antibodies to cholera ( A ), influenza A/H1N1 ( B ), influenza A/H3N2 ( C ) influenza B ( D ), hepatitis B ( E ), measles ( F ), S . Typhi ( G ), rabies ( H ), and mumps ( I ). The antibodies were added in the culture medium simultaneously with GWI serum for two days. Most nuclei appeared healthy and stained with DAPI (blue); few nuclei were stained with TUNEL in Figure 7 A–G (red). In Figure 7 H,I, antibodies against rabies and mumps are shown to have no effect, as most nuclei appear stained red with TUNEL.

    Article Snippet: For this assay, the following antibodies were each incubated with GWI serum: anti-hemagglutinin (HA)–H1N1 (Cat. No. 11055-RP01), anti-HA–H3N2 (Cat. No. 11715-RP01), anti-HA–B (Cat. No.11053-RP01), strains of influenza (polyclonal, Sino Biological, Wayne, PA, USA); anti-Salmonella (Cat. No. PA1-20811, polyclonal, ThermoFisher Scientific, Rockford, IL, USA); anti-Japanese encephalitis virus (Cat. No. PA5-32237, polyclonal, ThermoFisher Scientific, Rockford, IL, USA); anti-Yersinia pestis (Cat. No. MA1-23074, monoclonal, ThermoFisher Scientific, Rockford, IL, USA); anti-hepatitis virus B (Cat. No. ab9193, polyclonal, Abcam, Cambridge, UK); anti-cholera toxin (monoclonal, Cat. No. LS-C142039, LS Bio, Seattle, WA, USA); anti-Yellow fever (Cat. No.3576, ThermoFisher Scientific, Rockford, IL, USA); anti-varicella zoster (Cat. No.LS-132860/58089, LS Bio, Seattle, WA, USA); anti-anthrax protective antigen (Cat. No. CPBT-66806RA, polyclonal, Creative Diagnostics, Shirley, NJ, USA); anti-mumps virus (Cat. No. MBS320375, monoclonal, MyBioSource, San Diego, CA, USA); anti-adenovirus (Cat. No. LS-C63691/120157, Seattle, WA, USA); anti-polio virus (Cat. No. ab22450, monoclonal, abcam, Cambridge, UK); anti-clostridium botulinum B toxoid activity (polyclonal, Cat. No. ab83064, abcam, Cambridge, UK); anti-measles (monoclonal, Cat. No. DMABT-H21849 Creative Diagnosticss, Shirley, NJ, USA).

    Techniques: Staining, TUNEL Assay